Latest news with #IDSolutions
Yahoo
26-05-2025
- Business
- Yahoo
Qiagen and ID Solutions Partner to Enhance Digital PCR Assays for Oncology Research
On Friday, Qiagen (NYSE:QGEN) announced a new commercial collaboration and joint marketing agreement with French company ID Solutions to expand the availability of digital polymerase chain reaction (dPCR) assays for oncology research applications. The partnership aims to use Qiagen's global reach and automation expertise with ID Solutions' assay development and manufacturing capabilities to strengthen Qiagen's position in oncology research. A scientist in a lab coat using the latest medical equipment for nucleic acid purification. Under the terms of the agreement, ID Solutions will produce and supply dPCR assays specifically for non-clinical research use on Qiagen's QIAcuity platforms. These assays are designed to identify multiple mutations simultaneously in cell-free DNA extracted from plasma and genomic DNA from formalin-fixed, paraffin-embedded tissue samples. Qiagen will initially market these kits in Europe, with plans for future expansion into other regions. The newly added assays will complement Qiagen's current PanCancer Kits for detecting various hallmark mutations in DNA from diverse sample types, as well as over 200 locked nucleic acid (LNA) mutation assays. For customers, this collaboration translates into streamlined access to ready-to-use assays optimized for QIAcuity in non-clinical oncology research, which promise results in less than a day. Qiagen (NYSE:QGEN) provides sample-to-insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. While we acknowledge the potential of QGEN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than QGEN and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-05-2025
- Business
- Yahoo
Qiagen and ID Solutions Partner to Enhance Digital PCR Assays for Oncology Research
On Friday, Qiagen (NYSE:QGEN) announced a new commercial collaboration and joint marketing agreement with French company ID Solutions to expand the availability of digital polymerase chain reaction (dPCR) assays for oncology research applications. The partnership aims to use Qiagen's global reach and automation expertise with ID Solutions' assay development and manufacturing capabilities to strengthen Qiagen's position in oncology research. A scientist in a lab coat using the latest medical equipment for nucleic acid purification. Under the terms of the agreement, ID Solutions will produce and supply dPCR assays specifically for non-clinical research use on Qiagen's QIAcuity platforms. These assays are designed to identify multiple mutations simultaneously in cell-free DNA extracted from plasma and genomic DNA from formalin-fixed, paraffin-embedded tissue samples. Qiagen will initially market these kits in Europe, with plans for future expansion into other regions. The newly added assays will complement Qiagen's current PanCancer Kits for detecting various hallmark mutations in DNA from diverse sample types, as well as over 200 locked nucleic acid (LNA) mutation assays. For customers, this collaboration translates into streamlined access to ready-to-use assays optimized for QIAcuity in non-clinical oncology research, which promise results in less than a day. Qiagen (NYSE:QGEN) provides sample-to-insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. While we acknowledge the potential of QGEN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than QGEN and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
QGEN Stock Might Gain Following New Partnership With ID Solutions
QIAGEN N.V. QGEN recently entered into a commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays, to expand the availability of dPCR assays for oncology research applications. The latest partnership is likely to expand QIAGEN's position in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research. Following the announcement, shares of QIAGEN remained unchanged at $42.32 yesterday. QIAGEN's long-term business strategy involves entering into strategic alliances as well as making marketing and distribution arrangements with academic, corporate and other partners relating to the development, commercialization, marketing and distribution of certain of their existing and potential products. In line with this, QIAGEN's partnership with McGill University is aimed at enhancing its position in North America's $1.8 billion microbiome research market. Additionally, the company announced a collaboration with Eli Lilly and Company to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes, which can play a key role in Alzheimer's disease diagnosis. As a result, we expect the new partnership with ID Solutions to positively boost the market sentiment toward QGEN stock. QIAGEN has a market capitalization of $9.16 billion. The company's earnings yield of 5.5% compares favorably to the industry's -33.5%. In the trailing four quarters, it delivered an average earnings surprise of 4.93%. Under the agreement, ID Solutions will manufacture and supply dPCR assays for non-clinical research use on QIAGEN's QIAcuity platforms. These assays are optimized to simultaneously detect multiple mutations in cell-free DNA (cfDNA) from plasma and genomic DNA (gDNA) from formalin-fixed, paraffin-embedded (FFPE) tissue. QIAGEN will commercialize these kits starting with Europe, with the potential for future expansion into other regions. The agreement supports QIAGEN's strategic focus on accelerating the adoption of the QIAcuity dPCR platform in oncology research. The new assays will expand QIAGEN's portfolio and complement the existing PanCancer Kits for detecting multiple hallmark mutations in DNA. The combination of QIAGEN's global reach and automation expertise with the assay development and manufacturing capabilities of ID Solutions will strengthen QIAGEN's position in oncology research. For customers, this partnership translates into streamlined access to ready-to-use assays optimized for QIAcuity in non-clinical oncology research, expanding beyond the current menu, enabling results in less than a day and meeting the growing demand for deeper molecular insights. Image Source: Zacks Investment Research Per the report from Research and Markets, the global digital PCR market was valued at $678.1 million in 2023 and is poised to reach $3.35 billion by 2034, marking a remarkable compound annual growth rate (CAGR) of 15.75% during 2024-2034. The market has been experiencing significant growth, primarily fueled by the rising adoption of personalized medicine to screen and diagnose genetic disorders. Additionally, the growing prevalence of infectious diseases is driving the demand for dPCR. Earlier this month, QIAGEN signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. The acquisition adds Franklin — Genoox's flagship cloud-based community platform — to the QIAGEN Digital Insights ('QDI') portfolio. It further strengthens QIAGEN's leadership in genetic interpretation for clinical genomics applications. In the past year, QGEN's shares have lost 5.9% compared with the industry's 17.5% decline. The company currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are AngioDynamics ANGO, STERIS STE and DexCom DXCM. AngioDynamics, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated earnings growth rate of 23.7% for 2025. You can see the complete list of today's Zacks #1 Rank stocks here. ANGO's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 70.85%. Veracyte's shares have risen 49.2% in the past year compared with the industry's 5.5% growth. STERIS, carrying a Zacks Rank #2 at present, has an estimated growth rate of 10.8% for 2025. STE's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.61%. Its shares have risen 34.1% compared with the industry's 7.7% growth in the past year. DexCom, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 23.2% for 2025. Its earnings surpassed estimates in two of the trailing four quarters and missed in the other two, delivering an average surprise of 0.47%. DXCM's shares have risen 26.4% against the industry's 15.7% decline in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
23-05-2025
- Business
- Yahoo
Qiagen and ID Solutions collaborate on dPCR assays for oncology research
Qiagen has entered a commercial collaboration and joint marketing agreement with French company ID Solutions to expand the availability of digital polymerase chain reaction (dPCR) assays for applications in oncology research. This collaboration aims to leverage Qiagen's automation experience and worldwide presence, combined with ID Solutions' assay development and manufacturing offerings. It is said to bolster Qiagen's position in oncology research. According to the agreement, ID Solutions will produce and supply dPCR assays for use in non-clinical research on Qiagen's QIAcuity platforms. The assays are designed to identify several mutations in cell-free DNA (cfDNA) from plasma and genomic DNA (gDNA) from paraffin-embedded (FFPE), formalin-fixed tissue samples. Qiagen will initially market these kits in Europe, with the potential for upcoming expansion into other areas. The collaboration supports the company's focus on expediting the QIAcuity dPCR platform adoption in oncology research. The assays are said to widen Qiagen's portfolio and complement the current PanCancer Kits for multiple hallmark mutation detection in DNA from varied sample types and more than 200 locked nucleic acid (LNA) mutation assays. These LNA assays are available through the company's GeneGlobe platform, which is said to integrate assays that are pre-designed with a database of over 10,000 biological entities, including microRNAs (miRNAs), pathogens, pathways, and genes. ID Solutions is committed to developing its assays for research use only on fully integrated platforms, aligning with the partnership's objectives. Qiagen noted that for customers, this collaboration means access to ready-to-use assays that are optimised for QIAcuity in non-clinical oncology research, delivering results in less than a day. Qiagen Europe, Middle East and Africa (EMEA) commercial operations head and vice-president Simona Grandits said: "Through our collaboration with ID Solutions, we are reinforcing our commitment at Qiagen to providing comprehensive dPCR solutions on QIAcuity that address critical needs in oncology research. "This agreement expands our assay portfolio, strengthens our position in oncology research, and supports faster, more reproducible results on the QIAcuity platform for our customers." Earlier this month, Qiagen's QIAstat-Dx Gastrointestinal Panel 2 Mini B received clearance from the US Food and Drug Administration, expanding the company's syndromic testing offerings in the country. "Qiagen and ID Solutions collaborate on dPCR assays for oncology research" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Business Wire
22-05-2025
- Business
- Business Wire
QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications. The combination of QIAGEN's global reach and automation expertise with the assay development and manufacturing capabilities of ID Solutions will strengthen QIAGEN's position in oncology research. Under the agreement, ID Solutions will manufacture and supply dPCR assays for non-clinical research use on QIAGEN's QIAcuity platforms. These assays are optimized to simultaneously detect multiple mutations in cell-free DNA (cfDNA) from plasma and genomic DNA (gDNA) from formalin-fixed, paraffin-embedded (FFPE) tissue. QIAGEN will commercialize these kits starting in Europe as the first region, with the potential for future expansion into other regions. This agreement supports QIAGEN's strategic focus on accelerating the adoption of the QIAcuity dPCR platform in oncology research. The new assays expand QIAGEN's portfolio, complementing the existing PanCancer Kits for detecting multiple hallmark mutations in DNA from diverse sample types and over 200 LNA (locked nucleic acid) Mutation Assays available via its GeneGlobe platform. This unique platform integrates pre-designed assays with a database of more than 10,000 biological entities, including genes, miRNAs, pathogens and pathways. "Through our collaboration with ID Solutions, we are reinforcing our commitment at QIAGEN to providing comprehensive dPCR solutions on QIAcuity that address critical needs in oncology research," said Simona Grandits, Vice President, Head of Commercial Operations for the Europe, Middle East and Africa (EMEA) Region at QIAGEN. "This agreement expands our assay portfolio, strengthens our position in oncology research, and supports faster, more reproducible results on the QIAcuity platform for our customers." The partnership aligns with ID Solutions mission to develop its assays for research use only on fully integrated platforms. "Partnering with QIAGEN enables us to extend the reach of our high-quality dPCR assays to more laboratories," said Lise Grewis, CEO, ID Solutions. "Together, we're enabling faster adoption of dPCR in oncology research with robust, reliable results." For customers, this partnership translates into streamlined access to ready-to-use assays optimized for QIAcuity in non-clinical oncology research, expanding beyond the current menu, enabling results in less than a day and meeting the growing demand for deeper molecular insights. To learn more about QIAGEN's dPCR solutions and the new assays available through this partnership, visit About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit About ID Solutions ID Solutions is a French company specialized in the development of molecular biology solutions for research and diagnostics in human oncology and infectious diseases. Founded in 2016 and based in Montpellier, ID Solutions has established capabilities for innovation, offering high-performance tools to support oncology departments across France. The company provides comprehensive solutions covering pre-analytical, analytical and interpretation stages, ensuring reliable, rapid and standardized molecular typing results. With a team of specialists in nucleic acid extraction, molecular biology and oncology, ID Solutions is committed to improving patient care through precision medicine and early detection of tumors. For more information, visit Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Source: QIAGEN N.V. Category: Oncology
